News

• 09/01/10
  Afferent Pharmaceuticals Presents Data Supporting Use of P2X3 Antagonists in Reducing Bone Cancer Pain
  <<click here for release>>

• 08/25/10
  Afferent Pharmaceuticals Announces Data Supporting Potential Utility of Proprietary P2X3 Antagonists in Regulating Bladder Reflexes
  <<click here for release>>

• 1/26/10
  Afferent Pharmaceuticals Names Bruce G. McCarthy, M.D., as CEO
  <<click here for release>>

• 12/16/09
  Roche Licenses First-in-Class Treatments for Chronic Pain to Afferent Pharmaceuticals; Afferent Secures $23 Million in Series A Financing
  <<click here for release>>

News & Events

09/01/10

Afferent Pharmaceuticals Presents Data Supporting Use of P2X3 Antagonists in Reducing Bone Cancer Pain
Preclinical Findings Presented at the 13th World Congress on Pain in Montreal
<<click here for release>>

08/25/10

Afferent Pharmaceuticals Announces Data Supporting Potential Utility of Proprietary P2X3 Antagonists in Regulating Bladder Reflexes
Preclinical Findings Presented at the 2010 Joint Annual Meeting of the International Continence Society and the International Urogynecological Association
<<click here for release>>

01/26/10

Afferent Pharmaceuticals Names Bruce G. McCarthy, M.D., as CEO
Neuroscience Industry Veteran to Lead Development of Chronic Pain Treatments; Technology Targets Novel Biological Pathway
<<click here for release>>

12/16/09

Roche Licenses First-in-Class Treatments for Chronic Pain to Afferent Pharmaceuticals; Afferent Secures $23 Million in Series A Financing
Pappas, Third Rock, Domain and New Leaf Launch New Company Centered on Novel Pain Management Technology; Afferent to Initiate Clinical Trials in First Half of 2010
<<click here for release>>